Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy.

Suzuki C, Blomqvist L, Sundin A, Jacobsson H, Byström P, Berglund Å, Nygren P, Glimelius B.

Ann Oncol. 2012 Apr;23(4):948-54. doi: 10.1093/annonc/mdr350. Epub 2011 Aug 10.

PMID:
21832285
[PubMed - indexed for MEDLINE]
Free Article
2.

Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial.

Giessen C, Laubender RP, Fischer von Weikersthal L, Schalhorn A, Modest DP, Stintzing S, Haas M, Mansmann UR, Heinemann V.

Cancer Sci. 2013 Jun;104(6):718-24. doi: 10.1111/cas.12148. Epub 2013 Apr 15.

PMID:
23480146
[PubMed - indexed for MEDLINE]
3.

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J.

J Clin Oncol. 2010 Nov 1;28(31):4706-13. doi: 10.1200/JCO.2009.27.6055. Epub 2010 Oct 4.

PMID:
20921462
[PubMed - indexed for MEDLINE]
4.

Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.

Delaunoit T, Alberts SR, Sargent DJ, Green E, Goldberg RM, Krook J, Fuchs C, Ramanathan RK, Williamson SK, Morton RF, Findlay BP.

Ann Oncol. 2005 Mar;16(3):425-9. Epub 2005 Jan 27.

PMID:
15677624
[PubMed - indexed for MEDLINE]
Free Article
5.

Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.

Machida N, Yoshino T, Boku N, Hironaka S, Onozawa Y, Fukutomi A, Yamazaki K, Yasui H, Taku K, Asaka M.

Jpn J Clin Oncol. 2008 Oct;38(10):689-94. doi: 10.1093/jjco/hyn086.

PMID:
18845522
[PubMed - indexed for MEDLINE]
Free Article
6.

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL.

N Engl J Med. 2000 Sep 28;343(13):905-14.

PMID:
11006366
[PubMed - indexed for MEDLINE]
Free Article
7.

Evaluation of predictive markers for patients with advanced colorectal cancer.

Byström P, Berglund Å, Nygren P, Wernroth L, Johansson B, Larsson A, Glimelius B.

Acta Oncol. 2012 Sep;51(7):849-59. doi: 10.3109/0284186X.2012.705020.

PMID:
22974092
[PubMed - indexed for MEDLINE]
8.

Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels.

Kim S, Dobi E, Jary M, Monnien F, Curtit E, Nguyen T, Lakkis Z, Heyd B, Fratte S, Cléau D, Lamfichekh N, Nerich V, Guiu B, Demarchi M, Borg C.

BMC Cancer. 2013 Dec 27;13:611. doi: 10.1186/1471-2407-13-611.

PMID:
24373251
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.

Malka D, Boige V, Jacques N, Vimond N, Adenis A, Boucher E, Pierga JY, Conroy T, Chauffert B, François E, Guichard P, Galais MP, Cvitkovic F, Ducreux M, Farace F.

Ann Oncol. 2012 Apr;23(4):919-27. doi: 10.1093/annonc/mdr365. Epub 2011 Aug 8.

PMID:
21825101
[PubMed - indexed for MEDLINE]
Free Article
10.

Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.

Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM.

J Clin Oncol. 2008 Dec 10;26(35):5721-7. doi: 10.1200/JCO.2008.17.7147. Epub 2008 Nov 10.

PMID:
19001325
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer.

Saunders MP, Hogg M, Carrington B, Sjursen AM, Allen J, Beech J, Swindell R, Valle JW.

Br J Cancer. 2004 Oct 18;91(8):1447-52.

PMID:
15452550
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.

Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. Review.

PMID:
18462574
[PubMed - indexed for MEDLINE]
Free Article
13.

A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer.

Glimelius B, Sørbye H, Balteskard L, Byström P, Pfeiffer P, Tveit K, Heikkilä R, Keldsen N, Albertsson M, Starkhammar H, Garmo H, Berglund A.

Ann Oncol. 2008 May;19(5):909-14. doi: 10.1093/annonc/mdm588. Epub 2008 Jan 21.

PMID:
18209013
[PubMed - indexed for MEDLINE]
Free Article
14.

Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer.

He L, Teng Y, Jin B, Zhao M, Yu P, Hu X, Zhang J, Li S, Gao Y, Liu Y.

BMC Cancer. 2010 Dec 14;10:681. doi: 10.1186/1471-2407-10-681.

PMID:
21156055
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil.

Hartmann JT, Oechsle K, Jäger E, Reis HE, Haag C, Niederle N, Wilke HJ, Pflüger KH, Batran SA, Büchele T, Hofheinz RD, Kanz L, Bokemeyer C.

Anticancer Drugs. 2004 Jun;15(5):473-7.

PMID:
15166621
[PubMed - indexed for MEDLINE]
16.

Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy.

Suzuki C, Blomqvist L, Hatschek T, Carlsson L, Einbeigi Z, Linderholm B, Lindh B, Loman N, Malmberg M, Rotstein S, Söderberg M, Sundqvist M, Walz TM, Aström G, Fujii H, Jacobsson H, Glimelius B.

Med Oncol. 2013 Mar;30(1):415. doi: 10.1007/s12032-012-0415-5. Epub 2013 Jan 16.

PMID:
23322522
[PubMed - indexed for MEDLINE]
17.

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.

Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G; Gruppo Oncologico Nord Ovest.

J Clin Oncol. 2007 May 1;25(13):1670-6.

PMID:
17470860
[PubMed - indexed for MEDLINE]
18.

Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study.

Aranda E, Valladares M, Martinez-Villacampa M, Benavides M, Gomez A, Massutti B, Marcuello E, Constenla M, Cámara JC, Carrato A, Dueñas R, Reboredo M, Navarro M, Díaz-Rubio E.

Ann Oncol. 2009 Feb;20(2):251-7. doi: 10.1093/annonc/mdn557. Epub 2008 Aug 20.

PMID:
18718892
[PubMed - indexed for MEDLINE]
Free Article
19.

Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.

Grothey A, Hedrick EE, Mass RD, Sarkar S, Suzuki S, Ramanathan RK, Hurwitz HI, Goldberg RM, Sargent DJ.

J Clin Oncol. 2008 Jan 10;26(2):183-9. doi: 10.1200/JCO.2007.13.8099.

PMID:
18182660
[PubMed - indexed for MEDLINE]
20.

Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.

Ducreux M, Malka D, Mendiboure J, Etienne PL, Texereau P, Auby D, Rougier P, Gasmi M, Castaing M, Abbas M, Michel P, Gargot D, Azzedine A, Lombard-Bohas C, Geoffroy P, Denis B, Pignon JP, Bedenne L, Bouché O; Fédération Francophone de Cancérologie Digestive (FFCD) 2000–05 Collaborative Group.

Lancet Oncol. 2011 Oct;12(11):1032-44. doi: 10.1016/S1470-2045(11)70199-1. Epub 2011 Sep 6.

PMID:
21903473
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk